A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures

NCT00698581 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
88
Enrollment
INDUSTRY
Sponsor class

Stopped An interim analysis revealed the study was unlikely to attain a positive outcome for the efficacy analysis. No safety concerns were detected.

Conditions

Interventions

Sponsor

UCB Pharma